Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Trading Update

Cyprotex Trading Update

13 December 2012 – Cyprotex PLC (AIM:CRX), the preclinical ADME-Tox services company, today provides an update on trading following the Company’s interim results on 6 September 2012.

For the first half of the year, Cyprotex announced a 5.1% increase in revenues to £3.72m with an operating loss of £189,000. While revenues up to the month of October were as expected, late November and December performance have been slightly softer than expected due to a delay in customers sending the compounds prior to the extended Christmas holiday period.

Revenues are ahead of 2011 comparables and the Company continues to trade profitably, however, we expect revenues will be slightly below market expectations with a commensurate drop in profit.

For further information:

Cyprotex PLC
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
ir@cyprotex.com
www.cyprotex.com

N+1 Singer (Nomad and broker to Cyprotex)
Tel: +44 (0)20 7496 3000
Shaun Dobson
shaun.dobson@n1singer.com
Jenny Wyllie
jenny.wyllie@n1singer.com
www.nplus1singer.com


FTI Consulting
Simon Conway
Mo Noonan
Tel: +44 (0) 20 7831 3113
cyprotex@fticonsulting.com
www.fticonsulting.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close